These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 29053578)

  • 1. Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis.
    Paragliola RM; Papi G; Pontecorvi A; Corsello SM
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29053578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of iatrogenic Cushing syndrome: questions of glucocorticoid withdrawal].
    Igaz P; Rácz K; Tóth M; Gláz E; Tulassay Z
    Orv Hetil; 2007 Feb; 148(5):195-202. PubMed ID: 17344139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in hypothalamic-pituitary-adrenal axis activity and in levels of proopiomelanocortin and corticotropin-releasing hormone-receptor 1 mRNAs in the pituitary and hypothalamus of the rat during chronic 'binge' cocaine and withdrawal.
    Zhou Y; Spangler R; Schlussman SD; Ho A; Kreek MJ
    Brain Res; 2003 Feb; 964(2):187-99. PubMed ID: 12576179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human corticotropin-releasing hormone test in patients with hypothalamo-pituitary-adrenocortical disorders.
    Fukata J; Shimizu N; Imura H; Hibi I; Tanaka K; Tanaka T; Nakagawa S; Takebe K; Kimura K; Yoshinaga K
    Endocr J; 1993 Oct; 40(5):597-606. PubMed ID: 7951526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corticotropin-releasing hormone links pituitary adrenocorticotropin gene expression and release during adrenal insufficiency.
    Muglia LJ; Jacobson L; Luedke C; Vogt SK; Schaefer ML; Dikkes P; Fukuda S; Sakai Y; Suda T; Majzoub JA
    J Clin Invest; 2000 May; 105(9):1269-77. PubMed ID: 10792002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of hypothalamo-pituitary-adrenocortical function in children by human corticotropin-releasing hormone (MCI-028) test.
    Tanaka T; Hibi I; Shimizu N; Imura H; Tanaka K; Fukata J; Fujieda K; Ichimura T; Kuribayashi T; Ito K
    Endocr J; 1993 Oct; 40(5):581-9. PubMed ID: 7951524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant infusion of ovine corticotropin-releasing hormone does not prevent suppression of the hypothalamus-pituitary-adrenal axis by dexamethasone in male rats.
    Huang TS
    J Endocrinol Invest; 1997; 20(7):393-6. PubMed ID: 9309537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of pulsatile human corticotropin-releasing hormone administration on the adrenal insufficiency that follows cure of Cushing's disease.
    Avgerinos PC; Nieman LK; Oldfield EH; Loughlin T; Barnes KM; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1989 May; 68(5):912-6. PubMed ID: 2541160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute glucocorticoid pretreatment suppresses stress-induced hypothalamic-pituitary-adrenal axis hormone secretion and expression of corticotropin-releasing hormone hnRNA but does not affect c-fos mRNA or fos protein expression in the paraventricular nucleus of the hypothalamus.
    Ginsberg AB; Campeau S; Day HE; Spencer RL
    J Neuroendocrinol; 2003 Nov; 15(11):1075-83. PubMed ID: 14622438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis.
    Beishuizen A; Thijs LG
    J Endotoxin Res; 2003; 9(1):3-24. PubMed ID: 12691614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ghrelin, hypothalamus-pituitary-adrenal (HPA) axis and Cushing's syndrome.
    Giordano R; Picu A; Broglio F; Bonelli L; Baldi M; Berardelli R; Ghigo E; Arvat E
    Pituitary; 2004; 7(4):243-8. PubMed ID: 16132204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and risk factors for hypothalamus-pituitary-adrenal axis suppression in infants receiving glucocorticoid eye drops after ocular surgery.
    Schmidt DC; Kessel L; Bach-Holm D; Main KM; Larsen DA; Bangsgaard R
    Acta Ophthalmol; 2023 Mar; 101(2):229-235. PubMed ID: 36165330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cushing's syndrome and adrenocortical insufficiency caused by topical steroids: misuse or abuse?
    Güven A; Gülümser O; Ozgen T
    J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1173-82. PubMed ID: 18183788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of CRH-Binding Protein (CRHBP) in Chickens: Molecular Cloning, Tissue Distribution and Investigation of Its Role as a Negative Feedback Regulator within the Hypothalamus-Pituitary-Adrenal Axis.
    Wan Y; Zhang Z; Lin D; Wang X; Huang T; Su J; Zhang J; Li J; Wang Y
    Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cushing's syndrome: from physiological principles to diagnosis and clinical care.
    Raff H; Carroll T
    J Physiol; 2015 Feb; 593(3):493-506. PubMed ID: 25480800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The kappa-opioid receptor agonist MR-2034 stimulates the rat hypothalamic-pituitary-adrenal axis: studies in vivo and in vitro.
    Calogero AE; Scaccianoce S; Burrello N; Nicolai R; Muscolo LA; Kling MA; Angelucci L; D'Agata R
    J Neuroendocrinol; 1996 Aug; 8(8):579-85. PubMed ID: 8866244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antiglucocorticoid and antiprogestin steroid RU 486 suppresses the adrenocorticotropin response to ovine corticotropin releasing hormone in man.
    Laue L; Chrousos GP; Loriaux DL; Barnes K; Munson P; Nieman L; Schaison G
    J Clin Endocrinol Metab; 1988 Feb; 66(2):290-3. PubMed ID: 2828406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of the hypothalamic-pituitary-adrenal axis.
    Papadimitriou A; Priftis KN
    Neuroimmunomodulation; 2009; 16(5):265-71. PubMed ID: 19571587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression.
    Scott LV; Dinan TG
    Life Sci; 1998; 62(22):1985-98. PubMed ID: 9627097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel in vitro perfusion system for the determination of hypothalamic-pituitary-adrenal axis responses.
    Moidel MA; Belz EE; Czambel RK; Rubin RT; Rhodes ME
    J Pharmacol Toxicol Methods; 2006; 53(3):264-71. PubMed ID: 16311047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.